par Karakike, Eleni 
;Scicluna, Brendon BP;Roumpoutsou, Maria;Mitrou, Ioannis;Karampela, Niki;Karageorgos, Athanasios;Psaroulis, Konstantinos;Massa, Eleni;Pitsoulis, Achillefs;Chaloulis, Panagiotis;Pappa, Evanthia;Schrijver, Irene IT;Frantzeskaki, Niki;Lada, Malvina;Dauby, Nicolas ;De Bels, David ;Floros, Ioannis;Anisoglou, Souzana;Antoniadou, Eleni;Patrani, Maria;Vlachogianni, Glykeria;Mouloudi, Eleni;Antoniadou, Anastasia;Grimaldi, David ;Roger, Thierry ;Wiersinga, W Joost;Tsangaris, Iraklis;Giamarellos-Bourboulis, Evangelos J
Référence Critical care, 26, 1, page (183)
Publication Publié, 2022
;Scicluna, Brendon BP;Roumpoutsou, Maria;Mitrou, Ioannis;Karampela, Niki;Karageorgos, Athanasios;Psaroulis, Konstantinos;Massa, Eleni;Pitsoulis, Achillefs;Chaloulis, Panagiotis;Pappa, Evanthia;Schrijver, Irene IT;Frantzeskaki, Niki;Lada, Malvina;Dauby, Nicolas ;De Bels, David ;Floros, Ioannis;Anisoglou, Souzana;Antoniadou, Eleni;Patrani, Maria;Vlachogianni, Glykeria;Mouloudi, Eleni;Antoniadou, Anastasia;Grimaldi, David ;Roger, Thierry ;Wiersinga, W Joost;Tsangaris, Iraklis;Giamarellos-Bourboulis, Evangelos JRéférence Critical care, 26, 1, page (183)
Publication Publié, 2022
Article révisé par les pairs
| Résumé : | Clarithromycin may act as immune-regulating treatment in sepsis and acute respiratory dysfunction syndrome. However, clinical evidence remains inconclusive. We aimed to evaluate whether clarithromycin improves 28-day mortality among patients with sepsis, respiratory and multiple organ dysfunction syndrome. |
